NDAORALTABLETPriority Review
Approved
Apr 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
29
Data completeness
7/8 — Comprehensive
Priority Review
CAPRELSA (vandetanib) by Sanofi is protein kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2011.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPRELSA (vandetanib) is an oral tyrosine kinase inhibitor that blocks multiple protein kinase pathways involved in tumor growth and angiogenesis. It is approved for medullary thyroid cancer and has been studied across 17 cancer indications including non-small-cell lung cancer, pancreatic cancer, and hepatocellular carcinoma. The drug works by inhibiting VEGFR, EGFR, and RET kinases to suppress tumor proliferation and neovascularization.
$3MPart D
LOE ApproachingDeclining
2.3 years to LOEMinimal commercial activity with <200 annual claims signals a small brand team focused on niche medullary thyroid cancer patients rather than broader oncology expansion.
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
Started May 2017
8 enrolled
Carcinoma, HepatocellularMetastatic Colorectal Cancer
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Started Apr 2015
160 enrolled
Neoplasms
Vandetanib in Advanced NSCLC With RET Rearrangement
Started Nov 2014
17 enrolled
Non Small Cell Lung Cancer
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Started Oct 2014
0PhaeochromocytomaParaganglioma
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Started Apr 2014
10 enrolled
Metastatic Medullary Thyroid Cancer
Worked on CAPRELSA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.